CAR-T Cell Therapy for Leukemia
GPTKB entity
Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:psychotherapy
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:age |
adult
pediatric |
| gptkbp:alternativeTo |
chemotherapy
bone marrow transplant |
| gptkbp:antigen |
gptkb:CD19
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:cost |
expensive
|
| gptkbp:developedBy |
gptkb:Novartis
gptkb:Kite_Pharma |
| gptkbp:effect |
high remission rates in relapsed/refractory leukemia
|
| https://www.w3.org/2000/01/rdf-schema#label |
CAR-T Cell Therapy for Leukemia
|
| gptkbp:mechanismOfAction |
genetically engineered T cells target cancer cells
|
| gptkbp:monitors |
oncologist
|
| gptkbp:notableProduct |
gptkb:Kymriah
gptkb:Yescarta |
| gptkbp:requires |
leukapheresis
lymphodepleting chemotherapy |
| gptkbp:sideEffect |
neurotoxicity
cytokine release syndrome |
| gptkbp:treatment |
leukemia
|
| gptkbp:usedFor |
B-cell acute lymphoblastic leukemia
|
| gptkbp:uses |
chimeric antigen receptor T cells
|
| gptkbp:bfsParent |
gptkb:Cell_Therapy
|
| gptkbp:bfsLayer |
6
|